Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.
Sammy HuygensCorine GeurtsvanKesselArvind GharbharanSusanne BogersNathalie WorpMarjan BoterHannelore I BaxLinda M KampschreurRobert-Jan HassingRoel B FietsHenriette LevengaPedro Miranda AfonsoMarion P G KoopmansBart J A RijndersBas B Oude MunninkPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Despite treatment with mAbs, morbidity and mortality of COVID-19 in ICPs remained substantial. Combination antiviral therapy should be further explored and may be preferred in severely ICPs.
Keyphrases
- sars cov
- monoclonal antibody
- end stage renal disease
- coronavirus disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- respiratory syndrome coronavirus
- copy number
- clinical trial
- hiv infected
- antiretroviral therapy
- intensive care unit
- patient reported outcomes
- mesenchymal stem cells
- acute respiratory distress syndrome
- dna methylation
- cell therapy